Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-01-25 (bloomberglaw.com)
Biogen Gets Final OK for $9.75 Million 401(k) Fee Settlement
Biogen Inc. received final court approval for a $9.75 million settlement with a class of workers challenging their 401(k) plan fees and investment options.
Read more
2023-11-29 (pharmiweb.com)
Pulmonary Fibrosis Biomarkers Market Anticipates a Remarkable Valuation of US$ 6.2 Billion by 2033-F
The global Pulmonary Fibrosis Biomarkers Market is on a trajectory of substantial growth, with a projected market size of US$ 4.1 billion in 2023 and an anticipated CAGR of 4.2% during the forecast period, propelling it to a valuation of US$ 6.2 billion by 2033.Key to this growth is the rapid adv...
Read more
2023-10-23 (reut.rs)
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.
Read more
2023-10-17 (pionline.com)
Companies move to settle ERISA lawsuits in third quarter
During the third quarter of 2023, 58 ERISA-related lawsuits were filed and/or updated. Each event represents the involved parties either reaching a settlement or filing an appeal, or a court decision was made.
Read more
2023-09-01 (bloomberglaw.com)
Biogen Gets Nod for $9.75 Million 401(k) Plan Fee Settlement
Biogen Inc.'s $9.75 million settlement with a class of workers challenging their 401(k) plan fees and investment options received initial approval from a federal judge in Boston.
Read more
2023-08-25 (pionline.com)
Biogen settles 401(k) lawsuit for $9.75 million
Biogen Inc. will pay $9.75 million to settle a lawsuit by 401(k) plan participants who alleged a series of ERISA violations.
Read more
2023-08-24 (bloomberglaw.com)
Biogen Signs $9.75 Million Settlement in 401(k) Fee Class Action
Biogen Inc. will pay $9.75 million to settle a class action challenging the fees and investment options in the Massachusetts-based biotechnology company’s retirement plan.
Read more
2023-07-05 (pionline.com)
After mediation, Biogen agrees to settle 401(k) lawsuit
Biogen Inc. will settle an ERISA lawsuit filed by participants in a company 401(k), according to a settlement notice.
Read more
2023-03-29 (breakingnews.ie)
High Court wrongly found public interest in cheaper drugs overrode patent holder rights | BreakingNews.ie
A judge at the Court of Appeal said the High Court erred in principle in considering that patent holder, Biogen, had a “monopoly to which it was not entitled”
Read more
2022-11-04 (masslawyersweekly.com)
FCA suit pays off for Boston firm, whistleblower client | Massachusetts Lawyers Weekly
History was made in at least two respects in September when Biogen Inc. agreed to pay $900 million to settle a False Claims Act whistleblower ...
Read more
2022-10-17 (mondaq.com)
First To File: Issue 4
Last week, a federal district court in West Virginia denied defendants' motions to dismiss and allowed an FCA action to proceed in another case involving an interpretation of Rule 9(b).
Read more
2022-10-10 (mondaq.com)
Biogen Settlement Summary
On Monday September 26, the Department of Justice announced a settlement resolving a lawsuit filed by former employee Michael Bawduniak
Read more